VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 2, 2016) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT) is pleased to announce that at the Annual General Meeting ("AGM") of the shareholders held on April 27, 2016, the following persons were elected as directors: Robert Di Silvio, Dr. Ronald Blanck, L.J. (Bud) Evans Jr., Dr. Alan L. Moloff, and Herbert A. Toms III. The Company's Stock Option Plan dated March 18, 2005, as amended March 5, 2008 and March 31, 2011, was also approved until the next AGM, subject to filing with the TSXV.

At a meeting of the board of directors of the Company held immediately following the AGM on April 27, 2016, Dr. Blanck was reelected as Chairman, Mark Hodge was reappointed as President and Chief Executive Officer and George Dorin was reappointed as Chief Financial Officer and Corporate Secretary. Dr. Ronald Blanck, Bud Evans and Robert Di Silvio were appointed to both the Company's Audit and Finance Committee and the Compensation and Corporate Governance Committee for the ensuing year. Bud Evans was selected to act as chair of the Audit and Finance Committee and Robert Di Silvio was selected to act as chair of the Compensation and Corporate Governance Committee.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. More information about Pyng is available on SEDAR at www.sedar.com under the Company's profile and on its website: www.pyng.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Safe Harbour Statement; Forward-Looking Statements: This release contains forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.